The Scientific Advisory Board (SAB) provides advice and guidance on the company’s lead anti-cancer development program. The nucleus of the board comprises three internationally renowned scientific leaders with expertise in immunology and development of antibody therapeutics: Sir Greg Winter (Chairman), Professor Douglas Fearon and Professor Terence Rabbits. Additional appointments are to follow.
The founding SAB members are:

Dr. Sir Gregory Winter
CBE, FRS, FMedSci, HonFRCP
Medical Research Council, Cambridge, UK

Sir Gregory Winter is a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge, and a Fellow of Trinity College Cambridge. He has served LMB as a Head of Division, Deputy Director and Acting Director. His scientific career has almost entirely been based in Cambridge where his work included protein sequencing (aminoacyl tRNA synthetases) and nucleic acid sequencing (influenze virus). He later developed technologies for making humanised antibodies (by grafting hypervariable regions from rodent antibodies to human antibodies) and also for making human antibodies in bacteria (by use of antibody repertories and phage display technologies). Most of the therapeutic antibodies on the market were developed using methods devised by him. He was a Founder and Director of Cambridge Antibody Technology (acquired by Astra Zeneca), a Founder and Director of Domantis (acquired by GSK) and more recently a Founder and Director of Bicycle Therapeutics. Sir Gregory has received numerous international prizes and awards, and in 2004 was knighted for services to Molecular Biology.

Professor Douglas Fearon
FRS, FRCP, FMedSci
University of Cambridge, UK

Douglas Fearon is Emeritus Sheila Joan Smith Professor of Immunology of Cambridge University, and Senior Group Leader of the CRUK Cambridge Research Institute. Before moving to Cambridge in 1997, he was Professor of Medicine at Harvard Medical School from 1984-1987 and at Johns Hopkins Medical School from 1987-1993 where he was director of the Division of Rheumatology. He is Member of the European Molecular Biology Organization (EMBO), a Fellow of the Royal Society (FRS), a Founder Fellow of the Academy of Medical Sciences (FMedSci), and a member of National Academy of Sciences of the United States. He is a Fellow of Trinity College, Cambridge. His scientific work has spanned several areas of immunology, including the innate immune system of complement, B and T cell biology, and most recently tumor immunology. His experience in the pharmaceutical and biotechnology area has included scientific advisory roles with Cambridge Antibody Technology, Domantis, GSK, and Kymab.

Professor Terence Rabbitts
FRS, FMedSci
Leeds Institute of Molecular Medicine, UK

Professor Rabbitts worked in Cambridge from 1973-2006 in the MRC Laboratory of Molecular Biology where he was head of the Division of Protein & Nucleic Acid Chemistry until 2002. He moved to become Director of the Leeds Institute of Molecular Medicine (from 2006 to 2010). He is a Member of the European Molecular Biology Organization (EMBO), a Fellow of the Royal Society (FRS) and a Founder Fellow of the Academy of Medical Sciences (FMedSci).
His scientific work includes pioneering the method of cDNA cloning, mapping human antibody genes, methods for chimaeric antibody production and single domains for blocking protein interactions inside cells. He defined the linkage of antibody and T cell receptor genes with cancer-specific chromosomal translocations, identified new families of oncogenes (such as the LMO2 and HOX11 families) and identified a first gene fusion in a solid tumor (FUS-CHOP). He developed the first gene fusion knock-in and also methods for creating chromosomal translocations de novo.
He has considerable experience in biotechnology companies. He was chairman of the SAB of Cambridge Antibody Technology and of Quadrant Healthcare until their respective IPOs, and he was a member the Domantis SAB until the company’s acquisition by GSK. He is currently Chairman of the SAB of Kymab and is a member of the SAB of Oryzon Genomics and of DiThera.